1. A Tissue-specific NF-κB inhibitor ameliorates inflammatory joint diseases. (4th April 2011) Authors: Sehnert, B; Burkhardt, H; Nimmerjahn, F; Pohle, S; Wessels, J; Vestweber, D; Zwerina, J; Schett, G; Dübel, S; Voll, R Journal: Annals of the rheumatic diseases Issue: Volume 69(2010)Supplement 2 Page Start: A45 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Antibodies to the endoplasmic reticulum-resident chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and systemic lupus erythematosus. (9th March 2010) Authors: Weber, C K; Haslbeck, M; Englbrecht, M; Sehnert, B; Mielenz, D; Graef, D; Distler, J H; Burkhardt, H; Schett, G; Voll, R E; Fürnrohr, B G Journal: Annals of the rheumatic diseases Issue: Volume 69(2010)Supplement 2 Page Start: A10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0103 Therapeutical targeting of antigen-induced arthritis with liposomal secretory leukocyte protease inhibitor (antileukoproteinase). (1st June 2001) Authors: Schneider, C; Söder, S; Sehnert, B; Voll, RE; Kalden, JR; Burkhardt, H Journal: Annals of the rheumatic diseases Issue: Volume 60(2001)Supplement 1 Page Start: A386 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗